Global Cystic Fibrosis (CF) Therapeutics Market, Trends, Analysis, Opportunities, Share and Forecast – 2019-2025

The global cystic fibrosis therapeutics market is expected to witness significant growth during the forecast period majorly due to the availability of personalized drug therapy & molecular prosthetics for the treatment of cystic fibrosis. Furthermore, rise in the prevalence of cystic fibrosis and a surge in awareness about cystic fibrosis across the globe boost the cystic fibrosis market trend. For instance, according to the Cystic Fibrosis Foundation Patient Registry, in the U.S. more than 30,000 people are living with cystic fibrosis and more than 70,000 worldwide.

In addition, approximately 1,000 new cases of CF are diagnosed each year and more than 75 % of people with Cystic fibrosis F are diagnosed by age 2. Moreover, an increase in R&D investments made by the government in the healthcare sector drives cystic fibrosis therapeutics market growth. However, the high cost of cystic fibrosis treatment and introduction of generic drugs hinder the growth of the market. Developing nations such as countries of the Asia-Pacific region are not so aware of reading the cystic fibrosis diagnosis of the newborns. In various nations, newborns are not tested for CF during birth and national registries are lacking in data, thereby hampering the cystic fibrosis market growth.

The global CF therapeutics market size was estimated at USD 3,920.5 million in 2018 and is expected to grow at a CAGR of 16.7% from 2018 to 2025

To request a sample copy or view summary of this report, click the link below:
http://www.digitsnmarkets.com/sample/4306-cystic-fibrosis-(cf)-therapeutics-market

Based on cystic fibrosis therapeutics market analysis, the CFTR modulators segment dominated the market in 2018 and is anticipated to continue its dominance during the forecast period. This is attributed to the increased usage of these drugs for the treatment of cystic fibrosis. This segment is also estimated to grow at the fastest rate during the forecast period. Further, the introduction of CFTR drugs, Kalydeco, Orkambi and Symdeko is one such innovation. These drugs are now widely being used for the treatment of cystic fibrosis and many other CFTR drugs are under clinical trials. The main target of these drugs is to increase the life expectancy of the patients. Moreover, advances in the diagnosis and therapeutics have significantly increased the survival of patients.

Europe constitutes the highest market share in the global cystic fibrosis therapeutics market in 2018. North America is owing to the increase in the incidence of cystic fibrosis. Moreover, an increase in governmental support for innovation and rise in funding of projects for R&D of various cystic fibrosis drugs further fuel the market growth in this region. The UK is the highest revenue contributor due to the increase in the prevalence of cystic fibrosis in this region. Moreover, a surge in national newborn screening programs in the UK propels market growth. In addition, many companies are involved in developing drugs for individuals who do not get benefitted from CFTR drugs. However, North America is projected to grow at the highest CAGR during the forecast period.

Key players operating in cystic fibrosis therapeutic markets are Genentech, Inc., Novartis AG, Gilead Sciences, Inc., Vertex Pharmaceuticals Incorporated, AbbVie Inc., GlaxoSmithKline Plc., Johnson & Johnson, Allergan plc, Pharmaxis Ltd., and Mylan N.V.

Contact Us :
Digits ‘N’ Markets
410 E Santa Clara Street, Unit #762
San Jose, CA 95113
Phone :+1 408-622-0123
Email: sales@digitsnmarkets.com
Website:- www.digitsnmarkets.com

About Digits N Markets:
Digits N Markets has a vast repository of latest market research reports on trending topics, niche company profiles, market size and other relevant data released by renowned publishers. We have access to the database related to niche markets and trending topics in various industries. We also update the data regularly to provide recent statistics to the client. Recent data and reports will be featured on our websites and clients will be able to access the same. Our clients will be able to benefit from qualitative & quantitative insights in the report which will support them in taking concrete business decisions.

This release was published on openPR.